A phase 1 study of KT-413, a dual degrader of IRAK4 and IMiD substrates, in patients with DLBCL
Project Term: March 11, 2020 - TBD
In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Key Studies with IRAK4 Protein Degraders for Future Development in Hematological Patients." Kymera received this strategic investment from LLS TAP to advance work in an emerging approach to cancer therapy, called “targeted protein degradation.” Whereas most targeted therapies inhibit or inactivate the proteins or genes that drive the cancer, targeted protein degradation harnesses the body’s natural system of ridding itself of unwanted, “old” or “broken” components of cells. Kymera received FDA clearance to begin the clinical study and patient enrollment is ongoing.
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio